Clinical Trial Search

Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants

Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes

Primary: Concordance of Blue Dye and Lymphoseek — 0.9767 Proportion of Lymph Nodes

Primary: Sentinel Lymph Node Positivity — 2 Participants

Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004

Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients

Primary: Postoperative Draining Time — 31; 32 days

Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…

Primary: Injection Site Clearance for Lymphoseek and 99mTc-Sulfur Colloid (SC). — 1.78; 0.045 minutes

Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…

Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704

Primary: Change in Stimulated C-peptide During a MMTT — 0.551; 0.506; 0.663; 0.425 Unitless back-transformed from log-scale — p== 0.5009

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Change in cSMS (Combined Symptom and Medication Score) — 2.6; 2.3; 4.5 score on a scale

Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants

Primary: Number of Cases Where Lymphatics Were Visualized by Blue Dye Versus by ICG Using the OnLume Imaging System — 5; 9 Participants

Primary: Overall Survival Rate

Primary: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit — 276; 200 Participants

Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient

Primary: Peak Neutralizing Antibody Titer — 1.37 Log YF antibody titer

Primary: Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments. — 21 participants

Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…

Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change

Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants

Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel…

Primary: Volume of Heart Receiving ≥ 5 Gray (Gy)/Cobalt Gray Equivalent (CGE) — 34.7; 2.7 % of heart receiving >= 5 Gray (Gy) — p=0.0078

Primary: Drain Duration — 23; 21 days

Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale